Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast~* Locally advanced (Stage 3B) or metastatic (Stage 4) disease~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~* Received up to 2 prior chemotherapy regimens (not including neoadjuvant/adjuvant therapy) for advanced or metastatic disease~* Participants with hormone-receptor positive tumors must have failed available lines of hormonal therapy unless hormone therapy was not tolerated or not clinically appropriate~* ≥ 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicities~* Radiographically measurable or evaluable disease~* An mGPS of 1 or 2 as defined below:~  * Criteria:~    1. modified Glasgow prognostic score (mGPS) of 1: CRP \> 10 mg/L and albumin ≥ 35 g/L~   2. mGPS of 2: C-reactive protein (CRP) \> 10 mg/L and albumin \< 35 g/L~Exclusion Criteria:~* Received prior treatment with capecitabine or fluoropyrimidine for advanced or metastatic disease~* Received more than 2 prior regimens for advanced or metastatic disease (not including hormonal therapy in the metastatic setting or neoadjuvant or adjuvant therapies)~* Unknown hormone-receptor status~* Ongoing radiation therapy or radiation therapy administered within 2 weeks of enrollment~* Concurrent anticancer therapy~* Inadequate renal, hepatic or bone marrow function~* Another current or previous malignancy within 2 years of study entry unless approved by the sponsor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A - Capecitabine and ruxolitinib (Type: EXPERIMENTAL): None
- Treatment B - Capecitabine and placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).